Other
Syncope
8
Pipeline Programs↗
1
Active Trials↗
6
Companies Involved↗
Syncope is an early-stage landscape with 8 programs across 6 companies. The most active players are Amgen, Novartis, Takeda. 2 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 2
No programs
Phase 32
Analysis
Trial Status
9
clinical trials
Completed7 · 78%
Unknown status1 · 11%
Not yet recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Stop Vasodepressor Drugs in Reflex Syncope
Completed·GGruppo Italiano Multidisciplinare per lo Studio della Sincope·Phase 3·NCT02137278·58 enrolled
Rapid Measurement of Adenosine in Syncope Patients
Completed·—·N/A·NCT05782712·235 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)